Rheumatology and Therapy（风湿病学和治疗杂志）影响因子_期刊投稿发表

期刊简介

Aims and ScopeRheumatology and Therapy is an international, open access, peer reviewed, rapid publication journal dedicated to the publication of high-quality clinical (all phases), observational, real-world and health outcomes research around the discovery, development, and use of rheumatologic therapies. Studies relating to diagnosis, pharmacoeconomics, public health, quality of life, and patient care, management, and education are also welcomed.Areas of focus include, but are not limited to, rheumatoid arthritis, gout, gouty arthritis, psoriatic arthritis, osteoarthritis, juvenile idiopathic/rheumatoid arthritis, systemic lupus erythematosus, axial spondyloarthritis, Pompe’s disease, inflammatory joint conditions, musculoskeletal conditions, systemic sclerosis, and fibromyalgia.The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, case reports, trial protocols, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Rheumatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research. Ethics and DisclosuresThe journal is a member of the Committee on Publication Ethics (COPE) and subscribes to its principles on how to deal with acts of misconduct thereby committing to investigate allegations of misconduct in order to ensure the integrity of research. Content in this journal is peer-reviewed (Single-blind). For more information on our publishing ethics policies, please see here: https://www.springer.com/gp/editorial-policiesRapid Publication The journal’s rapid publication timelines aim for a peer review decision within 2 weeks of submission. If an article is accepted it will be published online 3-4 weeks from acceptance. These rapid timelines are achieved through the combination of a dedicated in-house editorial team, who closely manage article workflow, and an extensive Editorial and Advisory Board who assist with rapid peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model this allows for the rapid and efficient communication of the latest research and reviews, allowing the advancement of rheumatologic therapies.Personal ServiceThe journal’s dedicated in-house editorial team offer a personal “concierge service” meaning that authors will always have a personal point of contact able to update them on the status of their manuscript. The editorial team check all manuscripts to ensure that articles conform to the most recent COPE, GPP and ICMJE publishing guidelines. This supports the publication of ethically sound and transparent research. We also encourage pre-submission enquiries and are always happy to provide a confidential assessment of manuscripts. Digital Features Rheumatology and Therapy offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by key summary points, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. If you consider that your paper would benefit from the inclusion of a digital feature, please let us know. Our editorial team are able to create high-quality slide decks and infographics in-house, and video abstracts through our partner Research Square, and would be happy to assist in any way we can. For further information about digital features, please contact the journal editor (see ‘Contact the Journal’ for email address), and see the ‘Guidelines for digital features and plain language summaries’ document under ‘Submission guidelines’.For examples of digital features please visit:https://springerhealthcare.com/expertise/publishing-digital-features/ PreprintsWe encourage posting of preprints of primary research manuscripts on preprint servers, authors' or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Posting of preprints is not considered prior publication and will not jeopardize consideration in our journals. Authors should disclose details of preprint posting during the submission process or at any other point during consideration in the journal. Once the manuscript is published, it is the author's responsibility to ensure that the preprint record is updated with a publication reference, including the DOI and a URL link to the published version of the article on the journal website.Please see here for further information on preprint sharing: https://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/submission/1302#c16721550Peer Review ProcessUpon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria.At least two extensive reviews are required to make the editorial decision. Where reviewer recommendations are conflicted, the editorial board will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed). Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case-by-case basis and should be sent to the journal editor, and authors are welcome to make rebuttals against individual reviewer comments if appropriate.Considering the time and effort required for a detailed peer review we reward our regular reviewers with the opportunity to publish without publication fees (pending peer review) for every three reviews completed per calendar year.CopyrightRheumatology and Therapy is published under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0.Publication FeesUpon acceptance of an article, authors will be required to pay the mandatory Rapid Service Fee of €5,250/$6,000/£4,300. The journal will consider fee discounts and waivers for developing countries and this is decided on a case-by-case basis.Open AccessAll articles published by Rheumatology and Therapy are published open access.ContactFor more information about the journal, including pre-submission enquiries, please contact charlotte.maddocks@springernature.com.

目标和范围风湿病学和治疗是一份国际性、开放获取、同行评审、快速出版的期刊，致力于发表高质量的临床（所有阶段）、观察性、现实世界和健康结果研究，围绕发现、开发和使用风湿病疗法。也欢迎与诊断、药物经济学、公共卫生、生活质量以及患者护理、管理和教育相关的研究。重点领域包括但不限于类风湿性关节炎、痛风、痛风性关节炎、银屑病关节炎、骨关节炎、幼年特发性/类风湿性关节炎、系统性红斑狼疮、中轴型脊柱关节炎、庞佩氏病、炎症性关节病症、肌肉骨骼病症、系统性硬化症和纤维肌痛。该杂志引起广大医疗保健专业人员的兴趣，并发表原创研究、评论、病例报告、试验方案、通信和信件。该期刊被全球读者阅读，并收到来自世界各地的投稿。风湿病学和治疗将考虑所有科学合理的研究，无论是积极的、证实的还是消极的数据。欢迎提交与国际和/或特定国家/地区的受众相关的意见，这在研究人员试图针对更具体的患者群体时至关重要。这种包容性的方法使该期刊能够协助传播所有科学和道德上合理的研究。道德与披露该期刊是出版道德委员会 (COPE) 的成员，并遵守其关于如何处理不当行为的原则，从而承诺调查不当行为的指控，以确保研究的完整性。本期刊中的内容经过同行评审（单盲）。有关我们的出版道德政策的更多信息，请参见此处：https://www.springer.com/gp/editorial-policiesRapid Publication 该期刊的快速出版时间表旨在在提交后 2 周内做出同行评审决定。如果一篇文章被接受，它将在接受后的 3-4 周内在线发布。这些快速的时间表是通过密切管理文章工作流程的专门内部编辑团队以及协助快速同行评审的广泛编辑和顾问委员会的组合来实现的。这使得该期刊能够支持研究的快速传播，同时仍然提供强有力的同行评审。结合期刊的开放获取模式，可以快速有效地交流最新研究和评论，从而推动风湿病疗法的进步。个人服务该期刊专门的内部编辑团队提供个人“礼宾服务”，这意味着作者将始终有个人联系人能够更新他们手稿的状态。编辑团队检查所有手稿，以确保文章符合最新的 COPE、GPP 和 ICMJE 出版指南。这支持发表道德上合理和透明的研究。我们也鼓励投稿前查询，并随时乐意对稿件进行保密评估。数字功能 Rheumatology and Therapy 提供一系列附加功能，旨在提高期刊内容的知名度、读者群和教育价值。每篇文章都附有关键摘要点，为广大读者提供了内容的高效概述。文章可能附有通俗易懂的语言摘要，以帮助对该领域有一定了解但不具备深入专业知识的读者理解文章的科学内容和总体含义。该期刊还提供了包括各种类型的数字功能的选项，包括动画摘要、视频摘要、幻灯片、音频幻灯片、教学视频、信息图表、播客和动画。所有附加功能均按照与文章本身相同的高标准进行同行评审。如果您认为您的论文将受益于包含数字功能，请告诉我们。我们的编辑团队能够通过我们的合作伙伴 Research Square 在内部创建高质量的幻灯片和信息图表以及视频摘要，并且很乐意尽我们所能提供帮助。有关数字特征的更多信息，请联系期刊编辑（请参阅“联系期刊”以获取电子邮件地址），并参阅“提交指南”下的“数字特征和简明语言摘要指南”文件。有关数字特征的示例，请访问：https://springerhealthcare.com/expertise/publishing-digital-features/ 预印本我们鼓励在预印本服务器、作者或机构网站上发布主要研究手稿的预印本，并鼓励研究人员之间在社区预印本服务器或预印本评论上进行开放式交流平台。预印本的发布不被视为先前出版，不会影响我们期刊的考虑。作者应在提交过程中或在期刊考虑期间的任何其他时间点披露预印本发布的详细信息。手稿发表后，作者有责任确保预印本记录更新出版参考，包括 DOI 和期刊网站上文章已发表版本的 URL 链接。请参阅此处了解更多信息预印本共享：https://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/submission/1302#c16721550Peer Review Process提交后，编辑团队会评估手稿以确保它们适合期刊的目标和范围，并检查是否存在抄袭。所有合适的提交都将接受全面的单盲同行评审。审稿人是根据他们在主题领域的相关专业知识和出版历史来选择的。该杂志拥有大量的编辑和顾问委员会成员，他们根据上述标准被选中协助同行评审。至少需要两次广泛的评审才能做出编辑决定。如果审稿人的建议存在冲突，将联系编辑委员会以获得进一步的建议和主持决定。然后手稿要么被接受，要么被拒绝，要么作者需要进行主要或次要的修改（可能需要处理审稿人的评论和编辑的评论）。重新提交修改后的手稿后，将与对审稿人评论的回复一起进行评估，如果修改充分，将被接受发表。被接受的手稿随后由制作团队进行编辑和排版，然后再在线发布。对同行评审后的决定提出的上诉将逐案考虑，并应发送给期刊编辑，欢迎作者在适当的情况下对个别审稿人的评论进行反驳。考虑到详细的同行评审所需的时间和精力我们奖励我们的定期审稿人有机会在每个日历年完成的每三篇评论中免费发表文章（等待同行评审）。版权风湿病学和治疗根据知识共享署名-非商业许可发布，允许用户阅读、复制、分发, 并从材料中为非商业目的制作衍生作品，只要引用原作品的作者即可。作者将本文的任何商业用途的专有权转让给施普林格。有关知识共享署名-非商业许可的更多信息，请单击此处：http://creativecommons.org/licenses/by-nc/4.0。出版费用接受文章后，作者将需要支付强制性快速服务费5,250 欧元/6,000 美元/4,300 英镑。该期刊将考虑发展中国家的费用折扣和减免，这将根据具体情况决定。开放获取风湿病学和治疗发表的所有文章都是开放获取的。联系有关该期刊的更多信息，包括提交前查询，请联系 charlotte.maddocks@springernature.com。

《Rheumatology and Therapy》期刊已被查看：次